Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells

Pediatric Blood and Cancer

Volumn 59, Issue 7, 2012, Pages 1245-1251

  Xie, Chengzhi ^a,b   Edwards, Holly ^a   Lograsso, Salvatore B ^a   Buck, Steven A ^c   Matherly, Larry H ^a   Taub, Jeffrey W ^a,c   Ge, Yubin ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JILIN UNIVERSITY   (China)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Clofarabine; Histone deacetylase inhibitor; Pediatric acute myeloid leukemia; Synergistic antileukemic interaction; Valproic acid

Indexed keywords

CLOFARABINE; PROTEIN BAX; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; APOPTOSIS; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOUBLE STRANDED DNA BREAK; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; INFANT; LEUKEMIA CELL; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; WESTERN BLOTTING;

ADENINE NUCLEOTIDES; ADOLESCENT; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARABINONUCLEOSIDES; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CYTARABINE; DNA DAMAGE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 84867371231     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24152     Document Type: Article

References (33)

1. Manola KN. Cytogenetics of pediatric acute myeloid leukemia. Eur J Haematol 2009; 83: 391- 405.
2. Meshinchi S, Arceci RJ. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist 2007; 12: 341- 355.
3. Kaspers GJL, Zwaan CN. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 2007; 92: 1519- 1532.
4. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004; 103: 784- 789.
5. Abujamra AL, dos Santos MP, Roesler R, et al. Histone deacetylase inhibitors: A new perspective for the treatment of leukemia. Leuk Res 2010; 34: 687- 695.
6. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769- 784.
7. Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010; 19: 1049- 1066.
8. Bonate PL, Arthaud L, Cantrell WR, Jr., et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006; 5: 855- 863.
9. Faderl S, Gandhi V, Kantarjian HM. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. Curr Opin Hematol 2008; 15: 101- 107.
10. Faderl S, Gandhi V, Keating MJ, et al. The role of clofarabine in hematologic and solid malignancies-Development of a next-generation nucleoside analog. Cancer 2005; 103: 1985- 1995.
11. Kantarjian HM, Jeha S, Gandhi V, et al. Clofarabine: Past, present, and future. Leuk Lymphoma 2007; 48: 1922- 1930.
12. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006; 24: 1917- 1923.
13. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105: 940- 947.
14. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112: 1638- 1645.
15. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006; 108: 45- 51.
16. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102: 2379- 2386.
17. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003; 21: 1167- 1173.
18. Karp JE, Ricklis RM, Balakrishnan K, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007; 110: 1762- 1769.
19. Drummond DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45: 495- 528.
20. Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008; 14: 4500- 4510.
21. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23: 3923- 3931.
22. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, et al. Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008; 34: 206- 222.
23. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969- 6978.
24. Cimino G, Lo-Coco F, Fenu S, et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 2006; 66: 8903- 8911.
25. Xie C, Edwards H, Xu X, et al. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res 2010; 16: 5499- 5510.
26. Xu X, Xie C, Edwards H, et al. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. PLoS ONE 2011; 6: e17138, 1-11.
27. Su JM, Li XN, Thompson P, et al. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: A children's oncology group report. Clin Cancer Res 2011; 17: 589- 597.
28. Tallarida RJ. Drug synergism: Its detection and applications. J Pharmacol Exp Ther 2001; 298: 865- 872.
29. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621- 681.
30. Edwards H, Xie CZ, LaFiura KM, et al. RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: Role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood 2009; 114: 2744- 2752.
31. Ge Y, Dombkowski AA, LaFiura KM, et al. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 2006; 107: 1570- 1581.
32. Ge Y, Stout ML, Tatman DA, et al. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst 2005; 97: 226- 231.
33. Berman JN, Look AT. Targeting transcription factors in acute leukemia in children. Curr Drug Targets 2007; 8: 727- 737.